Merck's Zolina shows antitumor activity; PolyMedix gets $14M;

 @FierceBiotech: Explosion of cancer drug trials spurs a new approach. Article | Follow @FierceBiotech

 @JohnCFierce: Tengion is looking for $35M out of an IPO this week. The strategy: Aim real low and keep your fingers crossed. Article | Follow @JohnCFierce

> According to research published in The Lancet, Merck's cancer drug Zolina shows promising antitumor activity and is well tolerated when combined with short-term palliative radiotherapy in patients with advanced pelvic cancer. Article

> Ambrilia Biopharma and its subsidiary Cellpep Pharma have approved a proposed transaction in which Ambrilia and Cellpep would receive additional non-dilutive financing through the disposition of a limited partnership interest. Before expenses to be incurred in connection with this potential transaction, a gain in the amount of approximately $4M could be realized by Ambrilia and Cellpep upon the closing. Ambrilia release

> Hercules Technology Growth Capital will provide PolyMedix $14 million in credit facilities. PolyMedix anticipates that proceeds from the facility may be used to fund certain Phase III enabling activities for its two lead compounds, PMX-60056 and PMX-30063, including manufacturing and toxicology studies, as well as for other general corporate purposes. Release

> Roche's Genentech is just weeks away from starting to ramp up production at its $400 million campus in Hillsboro, Oregon. Report

And Finally... An analysis of dietary data from more than 400,000 men and women found only a weak association between high fruit and vegetable intake and reduced overall cancer risk. Report

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.